Cormedix Inc. (CRMD): Antony Pfaffle , Interim Chief Medical Officer of Cormedix Inc. sold 60,000 shares on May 13, 2016. The Insider selling transaction was reported by the company on May 17, 2016 to the Securities and Exchange Commission. The shares were sold at $2.74 per share for a total value of $160,966.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 1, 2015, Randy Milby (CEO) purchased 1,610 shares at $3.88 per share price.On Jun 25, 2015, Taunia Markvicka (director) purchased 4,000 shares at $4.81 per share price.Also, On Jun 4, 2015, Matthew Duffy (director) sold 30,000 shares at $6.48 per share price.On Jun 3, 2015, Antony Pfaffle (Interim Chief Medical Officer) sold 30,000 shares at $6.37 per share price.
CorMedix: On Monday, May 16, 2016 heightened volatility was witnessed in CorMedix which led to swings in the share price. The shares opened for trading at $2.7 and hit $2.87 on the upside , eventually ending the session at $2.86, with a gain of 5.54% or 0.15 points. The heightened volatility saw the trading volume jump to 1,78,993 shares. The 52-week high of the share price is $7.38 and the company has a market cap of $104 M . The 52-week low of the share price is at $1.15.
Company has been under the radar of several Street Analysts.CorMedix is Reiterated by FBR Capital to Outperform while Lowering the Price Target of the company shares to $ 6 from a previous price target of $7 . The Rating was issued on Mar 17, 2016.CorMedix is Initiated by FBR Capital to Outperform and the brokerage firm has set the Price Target at $7. The Rating was issued on Mar 3, 2016.
CorMedix Inc. (CorMedix) is a pharmaceutical company that in-licenses develops and commercializes prophylactic and therapeutic products for the treatment of infectious diseases in cardiac renal and oncology patients. The Company has in-licensed all of the products in its pipeline. The Company’s primary product is Neutrolin a catheter lock solution which is used the treatment of catheter-related infections and thrombosis in the central venous catheter markets such as dialysis critical care and oncology. It has the worldwide rights to develop and commercialize product candidates CRMD003 (Neutrolin) and CRMD004. The Company manufactures CRMD003 (Neutrolin) through Navinta LLC a United States-based active pharmaceutical ingredient (API) developer. The CRMD004 is the gel formulation of Neutrolin which is in the pre-clinical stage of development.